NEW YORK (GenomeWeb News) – Myriad Genetics said today it has licensed pharmacokinetic analysis technology from Saladax Biomedical for use in chemotherapy drug management.
 
Under the agreement, Myriad has gained an exclusive North American license for Saladax technology that allows doctors to personalize chemotherapy doses to improve the efficacy of the treatment and to minimize toxicity, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.